Chronic Obstructive Airway Disease
Sanofi and Regeneron’s Dupixent Secures Historic FDA Approval as First Biologic Treatment for COPD
Dupixent, COPD, FDA Approval, Biologic Treatment, Sanofi, Regeneron
AstraZeneca’s IL-33 Drug Shows Mixed Results in COPD Trials, Despite Phase 2 Setbacks
AstraZeneca, IL-33, COPD, tozorakimab, phase 2 trials, respiratory diseases
GSK’s Nucala Demonstrates Efficacy in COPD with Positive Phase III Trial Results
GSK, Nucala, COPD, Phase III trial, mepolizumab, chronic obstructive pulmonary disease, asthma, IL-5 antagonist, monoclonal antibody.
FDA Rejects Merck-Daiichi Sankyo’s Lung Cancer Drug, Approves New Treatments for COPD and Lymphoma
FDA, Merck, Daiichi Sankyo, NSCLC, COPD, Lymphoma, Patritumab Deruxtecan, Ensifentrine, Epkinly
GSK’s RSV Vaccine Wins Expected Expansion into At-Risk Adults Aged 50-59
GSK, RSV vaccine, Arexvy, FDA approval, adults aged 50-59, increased risk, respiratory syncytial virus, lower respiratory tract disease, medical conditions, chronic obstructive pulmonary disease, asthma, heart failure, diabetes.
FDA Delays Dupixent Decision for Uncontrolled COPD Treatment, EU Panel Recommends Approval
Dupixent, dupilumab, COPD, FDA, EU approval, Sanofi, Regeneron, uncontrolled COPD, treatment delay
FDA Delays Dupixent Decision for COPD by Three Months, EMA Recommends Approval
FDA, Dupixent, COPD, EMA, Regeneron, Sanofi, Priority Review, PDUFA, Boreas, Notus, Phase III Trials
Tezspire Clinical Trials by AstraZeneca and Amgen: Empowering Patient Choice in COPD Treatment
Tezspire, AstraZeneca, Amgen, clinical trials, COPD, patient choice, pivotal studies, treatment.
Verona Pharma Prepares $650 Million Funding Pool for Ensifentrine Launch Ahead of FDA Decision
Verona Pharma, COPD, Ensifentrine, FDA, funding pool, launch, clinical trials, chronic obstructive pulmonary disease
Sanofi Eyes COPD Treatment as Major Growth Driver for Dupixent, Says CEO
Sanofi, Dupixent, COPD, growth pillar, immunology, CEO, treatment, expansion, clinical trials, asthma, atopic dermatitis.